Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.00.

CGEN has been the topic of several analyst reports. Lake Street Capital started coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a report on Friday, July 17th. Leerink Partners dropped their price objective on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd.

Compugen Price Performance

CGEN stock opened at $2.38 on Tuesday. The firm has a market capitalization of $225.03 million, a P/E ratio of 6.43 and a beta of 2.77. The business’s 50-day moving average is $2.26 and its two-hundred day moving average is $2.27. Compugen has a 1 year low of $1.29 and a 1 year high of $3.23.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Compugen had a return on equity of 47.72% and a net margin of 47.97%.The business had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same quarter last year, the business posted ($0.08) EPS. On average, analysts expect that Compugen will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Compugen

Several large investors have recently bought and sold shares of CGEN. Bank Hapoalim BM acquired a new stake in Compugen in the fourth quarter valued at $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen during the 4th quarter worth about $38,000. Calamos Advisors LLC acquired a new position in shares of Compugen during the 1st quarter worth about $63,000. Franklin Resources Inc. purchased a new position in shares of Compugen in the 2nd quarter valued at about $56,000. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Compugen in the 1st quarter valued at about $68,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.